Who Paid My Doc
Edmond Wickham
Pediatric Endocrinology Richmond, VA Medical Doctor
NPI 1477566545 CMS profile 1031843
1250 E Marshall St, Pediatrics, Richmond, VA 23298
General payments
$1,529
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$78,328
Through program year 2024, Edmond Wickham of Richmond, VA is reported in the CMS Open Payments database as having received $1,529 across 3 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $78,328 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 60th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $1,500 | 2 | |
| 2023 | General | $29 | 1 |
Beside peers
- Edmond Wickham
- Pediatric Endocrinology median
- Middle half of Pediatric Endocrinology
- National median
In program year 2025, general payments to Edmond Wickham were reported at $0. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.
Show as a table
| Year | Edmond Wickham | Pediatric Endocrinology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $196 | $68–$845 | $163 |
| 2020 | $0 | $124 | $37–$722 | $114 |
| 2021 | $0 | $134 | $35–$691 | $132 |
| 2022 | $0 | $177 | $47–$726 | $149 |
| 2023 | $29 | $236 | $75–$887 | $160 |
| 2024 | $1,500 | $259 | $91–$979 | $164 |
| 2025 | $0 | $293 | $106–$1,640 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 24 drugsPart D claims
683
Drug cost
$330,171
Branded share of claims
61.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Trulicity Dulaglutide | Brand | 81 | $109,329 | |
| Ozempic Semaglutide | Brand | 51 | $75,541 | |
| Jardiance Empagliflozin | Brand | 35 | $43,213 | |
| Mounjaro Tirzepatide | Brand | 25 | $30,138 | |
| Januvia Sitagliptin Phosphate | Brand | 17 | $23,345 | |
| Tresiba Flextouch U-100 Insulin Degludec | Brand | 22 | $15,506 | |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | Brand | 56 | $6,617 | |
| Fiasp Flextouch Insulin Aspart (Niacinamide) | Brand | 12 | $6,502 | |
| Humalog Insulin Lispro | Brand | 22 | $6,049 | |
| Insulin Lispro Kwikpen U-100 Insulin Lispro | Brand | 16 | $2,987 |
The 10 drugs with the highest cost, of 24 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 11 billing codesPaid by Medicare
$10,966
Medicare patients
69
Services billed
189
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 72% | |
| Arthritis | 58% | |
| Chronic kidney disease | 48% | |
| Ischemic heart disease | 42% | |
| Heart failure | 35% | |
| Depression | 30% | |
| Atrial fibrillation | 28% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
3 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Endocrinology in Virginia
Kent Reifschneider
Pediatric Endocrinology · Norfolk, VA
Bryce Nelson
Pediatric Endocrinology · Richmond, VA
David Repaske
Pediatric Endocrinology · Charlottesville, VA
Eric Gyuricsko
Pediatric Endocrinology · Norfolk, VA
Melissa Schoelwer
Pediatric Endocrinology · Charlottesville, VA
Maria Farida Pingul
Pediatric Endocrinology · Fairfax, VA
Related records
Pediatric Endocrinology in Virginia
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Endocrinology
Everyone recorded under this specialty, nationwide.
Doctors in Virginia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.